Last reviewed · How we verify
Alemtuzumab (GZ402673)
Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion.
Alemtuzumab is a monoclonal antibody that binds to CD52 on the surface of lymphocytes, leading to their destruction and depletion. Used for Relapsing-remitting multiple sclerosis, Chronic lymphocytic leukemia (CLL).
At a glance
| Generic name | Alemtuzumab (GZ402673) |
|---|---|
| Also known as | Lemtrada |
| Sponsor | Genzyme, a Sanofi Company |
| Drug class | Monoclonal antibody (CD52 antagonist) |
| Target | CD52 |
| Modality | Small molecule |
| Therapeutic area | Immunology / Hematology |
| Phase | FDA-approved |
Mechanism of action
Alemtuzumab targets CD52, a cell surface antigen present on B cells, T cells, and other lymphocytes. Upon binding, it triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), resulting in rapid lymphocyte depletion. This immunosuppressive effect reduces autoreactive lymphocytes and is used therapeutically in autoimmune and hematologic conditions.
Approved indications
- Relapsing-remitting multiple sclerosis
- Chronic lymphocytic leukemia (CLL)
Common side effects
- Infusion reactions
- Lymphopenia
- Infections
- Autoimmune thyroid disease
- Immune thrombocytopenia
- Headache
- Nausea
Key clinical trials
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (PHASE3)
- LEMTRADA Pregnancy Registry in Multiple Sclerosis
- Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 (PHASE4)
- A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis (PHASE1)
- Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alemtuzumab (GZ402673) CI brief — competitive landscape report
- Alemtuzumab (GZ402673) updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI